Ampio provides update on osteoarthritis of the knee (oak) program, reiterates compelling data in earlier phase iii trials of ampion in severe oak

Englewood, colo., june 17, 2021 /prnewswire/ -- ampio pharmaceuticals (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today reported newly integrated data from four of its earlier clinical trials with consistent inclusion, exclusion, and demographic populations utilizing ampion for treating osteoarthritis of the knee (oak).
AMPE Ratings Summary
AMPE Quant Ranking